Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.

The inflammasome is a cytoplasmic multiprotein complex that promotes proinflammatory cytokine maturation in response to host- and pathogen-derived signals. Missense mutations in cryopyrin (NLRP3) result in a hyperactive inflammasome that drives overproduction of the proinflammatory cytokines IL-1β and IL-18, leading to the cryopyrin-associated periodic syndromes (CAPS) disease spectrum. Mouse lines harboring CAPS-associated mutations in Nlrp3 have elevated levels of IL-1β and IL-18 and closely mimic human disease. To examine the role of inflammasome-driven IL-18 in murine CAPS, we bred Nlrp3 mutations onto an Il18r-null background. Deletion of Il18r resulted in partial phenotypic rescue that abolished skin and visceral disease in young mice and normalized serum cytokines to a greater extent than breeding to Il1r-null mice. Significant systemic inflammation developed in aging Nlrp3 mutant Il18r-null mice, indicating that IL-1 and IL-18 drive pathology at different stages of the disease process. Ongoing inflammation in double-cytokine knockout CAPS mice implicated a role for caspase-1-mediated pyroptosis and confirmed that CAPS is inflammasome dependent. Our results have important implications for patients with CAPS and residual disease, emphasizing the need to explore other NLRP3-mediated pathways and the potential for inflammasome-targeted therapy.

[1]  O. Sanal,et al.  A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. , 2012, Clinical immunology.

[2]  L. Lenz,et al.  Distinct Licensing of IL-18 and IL-1β Secretion in Response to NLRP3 Inflammasome Activation , 2012, PloS one.

[3]  James L. Mueller,et al.  Cutting Edge: IL-6 Is a Marker of Inflammation with No Direct Role in Inflammasome-Mediated Mouse Models , 2012, The Journal of Immunology.

[4]  G. López-Castejón,et al.  Caspase-1: is IL-1 just the tip of the ICEberg? , 2012, Cell Death and Disease.

[5]  R. Goldbach-Mansky,et al.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)‐1 and an emerging role for cytokines beyond IL‐1 , 2012, Clinical and experimental immunology.

[6]  Jinfeng Liu,et al.  Non-canonical inflammasome activation targets caspase-11 , 2011, Nature.

[7]  F. Retornaz,et al.  Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. , 2011, Seminars in arthritis and rheumatism.

[8]  B. Cookson,et al.  Coordinated Host Responses during Pyroptosis: Caspase-1–Dependent Lysosome Exocytosis and Inflammatory Cytokine Maturation , 2011, The Journal of Immunology.

[9]  H. Hoffman,et al.  Autoinflammation: translating mechanism to therapy , 2011, Journal of leukocyte biology.

[10]  Zhenwu Lin,et al.  Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. , 2011, Inflammatory bowel diseases.

[11]  Dirk E. Smith.  The biological paths of IL‐1 family members IL‐18 and IL‐33 , 2011, Journal of leukocyte biology.

[12]  S. Özen,et al.  Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine , 2011, The Journal of Rheumatology.

[13]  A. Oikonomou,et al.  The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis , 2011, Annals of the rheumatic diseases.

[14]  A. Plebani,et al.  Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis , 2010, Annals of the rheumatic diseases.

[15]  A. King,et al.  An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury , 2010, The Journal of Immunology.

[16]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[17]  C. Dinarello.  Anti-inflammatory Agents: Present and Future , 2010, Cell.

[18]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[19]  D. Kastner,et al.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. , 2009, Immunity.

[20]  I. Mitroulis,et al.  Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. , 2008, The Netherlands journal of medicine.

[21]  Richard A. Flavell,et al.  The Nalp3 inflammasome is essential for the development of silicosis , 2008, Proceedings of the National Academy of Sciences.

[22]  C. Gabay,et al.  IL‐1, IL‐18, and IL‐33 families of cytokines , 2008, Immunological reviews.

[23]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[24]  A. Plebani,et al.  Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.

[25]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[26]  P. Emery,et al.  Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra , 2007, Annals of the rheumatic diseases.

[27]  E. Remmers,et al.  The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. , 2007, Arthritis and rheumatism.

[28]  D. Boyle,et al.  Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. , 2007, The Journal of allergy and clinical immunology.

[29]  J. Sarles,et al.  Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis , 2006, Journal of Inherited Metabolic Disease.

[30]  S. Orkin,et al.  The journey of developing hematopoietic stem cells , 2006, Development.

[31]  B. Becher,et al.  Interleukin 18–independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation , 2006, Nature Immunology.

[32]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[33]  C. Dinarello,et al.  Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. , 2005, Blood.

[34]  K. Beaumont,et al.  IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients , 2005, The Journal of Immunology.

[35]  B. Cookson,et al.  Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells , 2005, Infection and Immunity.

[36]  I. Iqbal,et al.  Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis , 2004, Expert opinion on biological therapy.

[37]  C. Dinarello,et al.  Differences in signaling pathways by IL-1beta and IL-18. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Emery,et al.  Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. , 2004, Arthritis and rheumatism.

[39]  G. Fantuzzi,et al.  Interleukin-18 and host defense against infection. , 2003, The Journal of infectious diseases.

[40]  C. Dinarello,et al.  Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. , 2003, Cancer research.

[41]  A. Thatayatikom,et al.  Mutation of a New Gene Encoding a Putative Pyrin-Like Protein Causes Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome , 2002, Pediatrics.

[42]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[43]  R. McIntyre,et al.  Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. , 2002, American journal of physiology. Heart and circulatory physiology.

[44]  S. Srinivasula,et al.  The PYRIN-CARD Protein ASC Is an Activating Adaptor for Caspase-1* , 2002, The Journal of Biological Chemistry.

[45]  H. Okamura,et al.  Neutrophil Proteinase 3-Mediated Induction of Bioactive IL-18 Secretion by Human Oral Epithelial Cells1 , 2001, The Journal of Immunology.

[46]  D. Broide,et al.  Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. , 2001, The Journal of allergy and clinical immunology.

[47]  G. Fantuzzi,et al.  A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. , 2001, Cytokine.

[48]  A. Harken,et al.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Fantuzzi,et al.  IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Fantuzzi,et al.  Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. , 1999, Immunity.